Lamivudina E Zidovudina Aurobindo (Zidovudine, Lamivudine)

Both agents are nucleoside analogues that enter cells and are phosphorylated to active triphosphate forms. These triphosphates compete with natural nucleosides for incorporation into viral DNA by reverse transcriptase. Incorporation causes premature chain termination, blocking the synthesis of proviral DNA and thereby suppressing HIV replication.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, weight, renal function, and overall treatment regimen. Healthcare providers follow established guidelines and adjust the regimen as needed for optimal viral suppression and safety.

The safety of zidovudine and lamivudine during pregnancy and lactation is not fully established, and the product is classified as pregnancy category unknown. Clinicians must weigh potential benefits against risks, consider alternative regimens, and follow local regulatory guidance when prescribing to pregnant or nursing individuals.

To place an enquiry, visit the product page on gnhindia.com and submit the required quantity using the online form. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lamivudina E Zidovudina combines two NRTIs, offering a synergistic blockade of reverse transcription. Compared with newer fixed‑dose combinations such as tenofovir/emtricitabine, it may have a different safety profile, including a higher incidence of hematologic effects. Choice of regimen depends on patient‑specific factors, resistance patterns, tolerability, and guideline recommendations.

The product should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the tablets out of reach of children and avoid exposure to direct sunlight or humidity that could compromise tablet integrity.

Lamivudina E Zidovudina is supplied as oral tablets. Patients should swallow the tablet whole with a glass of water, preferably with food to reduce gastrointestinal upset. Adherence to the prescribed dosing schedule is essential for maintaining viral suppression.

Serious adverse events include lactic acidosis, hepatic steatosis, severe bone‑marrow suppression (pancytopenia), and hypersensitivity reactions that may involve rash, fever, or organ involvement. Prompt medical evaluation is required if patients experience unexplained fatigue, abdominal pain, rapid weight loss, or signs of infection.

Patients with known hypersensitivity to zidovudine, lamivudine, or any excipients in the tablet should avoid the product. Caution is also advised for individuals with severe bone‑marrow suppression, active hepatitis, or significant renal or hepatic impairment, where alternative therapies may be more appropriate.